Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02274155 · ClinicalTrials.gov registry record · Phase 1
Anti-OX40 Antibody in Head and Neck Cancer Patients
A Phase 1 study, sponsored by Providence Health & Services.
- Completed
- Registry status
- Phase 1
- Development phase
- 17
- Enrollment target
NCT02274155 is a Phase 1 study that has completed, run by Providence Health & Services. The registered enrollment target is 17 participants.
The verdict
NCT02274155, a Phase 1 study, has completed, sponsored by Providence Health & Services.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 17 participants
- Enrollment target
Study Summary
The purpose of this study is to test the safety of the anti-OX40 antibody, MEDI6469, given prior to surgery in patients with advanced head and neck squamous cell carcinoma.
Interventions
- PROCEDURE Surgical Resection
- DRUG Anti-OX40 antibody administration
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2014-11-12 |
| Est. Completion | 2023-12-21 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02274155
The ClinicalTrials.gov registry entry for NCT02274155 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Providence Health & Services, which has 69 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Surgical Resection is the first listed.
NCT02274155 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02274155 about?
NCT02274155 is a clinical study titled "Anti-OX40 Antibody in Head and Neck Cancer Patients". The purpose of this study is to test the safety of the anti-OX40 antibody, MEDI6469, given prior to surgery in patients with advanced head and neck squamous cell carcinoma.
What is the current status of trial NCT02274155?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 17 participants. The study started on 2014-11-12. Estimated completion is 2023-12-21.
What interventions are being tested in trial NCT02274155?
The interventions under investigation include: Surgical Resection (PROCEDURE), Anti-OX40 antibody administration (DRUG).
Who is sponsoring clinical trial NCT02274155?
This trial is sponsored by Providence Health & Services, which has 69 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.